Valeant Pharmaceuticals International Announces 2013 Annual Meeting Results
Published: May 22, 2013
LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:
Ronald H. Farmer
Robert A. Ingram
G. Mason Morfit
J. Michael Pearson
Robert N. Power
Norma A. Provencio
Howard B. Schiller
Lloyd M. Segal
At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2014 annual meeting of shareholders; and approved the continuance of the Company from the Canada Business Corporations Act to the British Columbia Business Corporations Act.
The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
Laurie W. Little